Yahoo
Shanghai - Delayed Quote CNY

Kangmei Pharmaceutical Co., Ltd. (600518.SS)

1.2800 +0.0200 (+1.59%)
At close: October 30 at 3:00:02 PM GMT+8
View in AlphaSpace Currency in CNY All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
5,032,703.7581
5,252,215.0583
5,189,137.1997
4,874,016.1430
4,180,150.3295
Cost of Revenue
3,980,718.3986
4,203,085.9871
4,422,148.2575
4,042,159.4124
3,547,148.0357
Gross Profit
1,051,985.3595
1,049,129.0711
766,988.9421
831,856.7307
633,002.2939
Operating Expense
955,892.4268
937,446.3150
741,374.8798
786,691.9984
1,646,796.5780
Operating Income
96,092.9328
111,682.7561
25,614.0623
45,164.7323
-1,013,794.2842
Net Non Operating Interest Income Expense
-8,769.3696
-9,839.2770
-5,182.5662
-27,118.4930
-40,836.2443
Pretax Income
16,426.6643
43,115.9145
34,650.4399
110,366.6101
-2,664,049.6867
Tax Provision
28,946.8629
30,686.7445
22,568.2412
6,799.6780
29,750.1617
Net Income Common Stockholders
-14,741.6674
10,327.9978
8,573.6627
102,521.2311
-2,688,159.0434
Basic EPS
0.00
0.00
0.00
0.01
-0.19
Diluted EPS
0.00
0.00
0.00
0.01
-0.19
Basic Average Shares
12,309,384.6990
14,754,282.5290
14,289,437.8830
10,252,123.1110
14,148,205.4920
Diluted Average Shares
12,309,384.6990
14,754,282.5290
14,289,437.8830
10,252,123.1110
14,148,205.4920
Total Operating Income as Reported
8,589.1636
35,011.0998
-24,788.3983
86,666.2721
-1,777,539.3246
Rent Expense Supplemental
12,216.2020
8,793.1346
10,789.6565
12,210.1188
12,421.5109
Total Expenses
4,936,610.8254
5,140,532.3021
5,163,523.1374
4,828,851.4107
5,193,944.6137
Net Income from Continuing & Discontinued Operation
-14,741.6674
10,327.9978
8,573.6627
102,521.2311
-2,688,159.0434
Normalized Income
88,085.7840
128,405.1169
86,874.3780
79,825.0068
-2,145,417.2913
Interest Income
11,385.9733
10,501.3916
17,227.5457
30,743.7224
40,028.0676
Interest Expense
18,277.3356
18,665.6334
21,387.1360
56,154.2219
78,897.0757
Net Interest Income
-8,769.3696
-9,839.2770
-5,182.5662
-27,118.4930
-40,836.2443
EBIT
34,703.9999
61,781.5479
56,037.5759
166,520.8320
-2,585,152.6110
EBITDA
34,703.9999
372,867.6997
396,024.0206
512,696.8238
-2,219,462.6479
Reconciled Cost of Revenue
3,980,718.3986
4,203,085.9871
4,422,148.2575
4,042,159.4124
3,547,148.0357
Reconciled Depreciation
325,847.8974
311,086.1518
339,986.4447
346,175.9918
365,689.9632
Net Income from Continuing Operation Net Minority Interest
-14,741.6674
10,327.9978
8,573.6627
102,521.2311
-2,688,159.0434
Total Unusual Items Excluding Goodwill
-171,379.0857
-157,436.1588
-104,400.9537
24,186.3430
-723,655.6696
Total Unusual Items
-171,379.0857
-157,436.1588
-104,400.9537
24,186.3430
-723,655.6696
Normalized EBITDA
206,083.0856
530,303.8585
500,424.9743
488,510.4808
-1,495,806.9783
Tax Rate for Calcs
0.0004
0.0003
0.0003
0.0001
0.0003
Tax Effect of Unusual Items
-68,551.6343
-39,359.0397
-26,100.2384
1,490.1186
-180,913.9174
12/31/2022 - 3/19/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: